Conference Coverage

Complete Conference Coverage

Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited

Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited

Researchers observed increased real-world incidence of cardiomyopathy in patients treated with trabectedin compared with that seen in the phase 3 study of the drug.

POT1 Revealed as a Sarcoma Predisposition Gene

POT1 Revealed as a Sarcoma Predisposition Gene

Australian researchers identified the gene using whole-genome sequencing in patients enrolled in the International Sarcoma Kindred Study.

IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up

IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up

But, there was no difference in DFS, DMFS, or OS between the 2 treatment subtypes at 5 years following the conclusion of the original study.

Dosing Schedule May Be Key to Optimal Administration of Milademetan for Sarcoma Subtype

Dosing Schedule May Be Key to Optimal Administration of Milademetan for Sarcoma Subtype

The switch from a continuous to an intermittent dosing schedule appeared to cut the occurrence of thrombocytopenia in half.

Phase 2 Trial of Abemaciclib in Dedifferentiated Liposarcoma Meets Primary End Point

Phase 2 Trial of Abemaciclib in Dedifferentiated Liposarcoma Meets Primary End Point

A subset of patients experienced sustained clinical benefit and at least some objective tumor response.

Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed

Mouse-Dog-Human Preclinical Cancer Model for Osteosarcoma Proposed

Researchers suggested the use of comparative oncology to identify novel therapies that could have clinical applications in osteosarcoma.

ALK Fusions Thought to Be Oncogenic Drivers in Some Leiomyosarcomas

ALK Fusions Thought to Be Oncogenic Drivers in Some Leiomyosarcomas

Analysis of transcriptomic data revealed that a subset of patients with these smooth muscle sarcomas have ALK fusions that retain targetable ALK kinase domains.

Unfavorable Prognosis in Sarcoma May Be Linked to Tumor Involvement of Fascia

Unfavorable Prognosis in Sarcoma May Be Linked to Tumor Involvement of Fascia

Patients with fascia-infiltrating sarcoma appeared to have worse survival that those who had either strict superficial or deep soft tissue sarcomas.

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.

Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC

Pembrolizumab Alone or With Chemotherapy Prolongs OS in Recurrent/Metastatic HNSCC

Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs